EUVIMEDEUVIMED entdecken
Crossref

Randomized controlled pilot trial of extended-release buprenorphine vs. sublingual buprenorphine-naloxone in rural settings (RXR): Study rationale and design

Larissa J Mooney, Andrew J Saxon, Megan Black, Allison J Ober, Mitra Lewis, Robrina Walker, Jennifer McCormack, Christina Scheele, Yih-Ing Hser

Contemporary Clinical Trials · 2026

DOI: 10.1016/j.cct.2026.108288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2026. Verfasst von Larissa J Mooney und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, …. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Buprenorphine, Naloxone Drug Combination, Narcotic Antagonists, Buprenorphine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse, National Institute on Drug Abuse Clinical Trials Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rural communities continue to experience high overdose mortality rates and challenges retaining individuals with opioid use disorder (OUD) on medications for opioid use disorder (MOUD). The most recent formulation of injectable extended-release buprenorphine (XR-BUP) may improve treatment engagement and outcomes for people with OUD. OBJECTIVES: The RXR study (CTN-0102XR) aims to evaluate the feasibility of implementing XR-BUP in rural settings, acceptability of XR-BUP to clinic staff and patients, and effectiveness of XR-BUP compared with sublingual buprenorphine-naloxone (SL-BUP). STUDY DESIGN AND METHODS: This is an open-label randomized controlled trial (RCT) using intention-to-treat (ITT) analysis. Approximately 144 participants recruited from seven rural clinic sites will be randomized to receive XR-BUP or SL-BUP in a ratio of 2:1, and will receive study medication for 14 weeks. Participants in the XR-BUP condition will receive two weekly initiation dosages, followed by the target monthly dosage (128 mg) at Weeks 2, 6, and 10. Participants in the SL-BUP condition will receive medication on a similar schedule, with a target dose range of 16-24 mg/day. The main comparative effectiveness outcome measure is the number of monthly opioid negative urine drug screens (UDS) for non-prescribed opioids from Weeks 2-14. Feasibility and acceptability will be evaluated using mixed methods, combining participant survey and interview data from clinic administrators, providers, and patients. CONCLUSIONS: If demonstrated to be feasible and acceptable to participants and staff and there is evidence of effectiveness for people with OUD in reducing opioid use, XR-BUP may be considered an important option for addressing OUD in rural settings. CLINICALTRIALS: gov Identifier: NCT06023459.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersBuprenorphine, Naloxone Drug CombinationNarcotic AntagonistsBuprenorphineOpiate Substitution TreatmentHumansDelayed-Action PreparationsAdministration, SublingualPilot ProjectsRural PopulationFemaleRandomized Controlled Trials as TopicAdultMale

Stichwörter der Autor:innen

Extended-release buprenorphineMedication for opioid use disorderOpioid use disorderRuralSublingual buprenorphine

Substanzen

Delayed-Action PreparationsBuprenorphine, Naloxone Drug CombinationNarcotic AntagonistsBuprenorphine

Autor:innen und Institutionen

  • Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA. Electronic address: lmooney@mednet.ucla.edu.
  • Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.
  • Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
  • RAND Corporation, 1776 Main Street, Santa Monica, CA 90401, USA.
  • The Emmes Company, LLC, Rockville, MD, USA.

Förderung

  • NIDA NIH HHS
  • National Institute on Drug Abuse
  • National Institute on Drug Abuse Clinical Trials Network

Zitieren

APA

Mooney, L. J., Saxon, A. J., Black, M., Ober, A. J., Lewis, M., Walker, R., McCormack, J., Scheele, C., & Hser, Y. I. (2026). Randomized controlled pilot trial of extended-release buprenorphine vs. sublingual buprenorphine-naloxone in rural settings (RXR): Study rationale and design. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2026.108288

Vancouver

Mooney LJ, Saxon AJ, Black M, Ober AJ, Lewis M, Walker R, et al. Randomized controlled pilot trial of extended-release buprenorphine vs. sublingual buprenorphine-naloxone in rural settings (RXR): Study rationale and design. Contemporary Clinical Trials. 2026. doi:10.1016/j.cct.2026.108288

BibTeX
@article{Mooney2026,
  author = {Mooney, Larissa J and Saxon, Andrew J and Black, Megan and Ober, Allison J and Lewis, Mitra and Walker, Robrina and McCormack, Jennifer and Scheele, Christina and Hser, Yih-Ing},
  title = {Randomized controlled pilot trial of extended-release buprenorphine vs. sublingual buprenorphine-naloxone in rural settings (RXR): Study rationale and design},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  doi = {10.1016/j.cct.2026.108288}
}
Kostenlos starten →